New migraine drug tested on 3,000 patients in Real-World setting
NCT ID NCT06439628
First seen Feb 06, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study looks at how well Rimegepant works for treating migraine attacks in everyday life. About 3,000 adults with migraines in China will take the drug as needed and report their pain levels, satisfaction, and quality of life over a year. The goal is to see if Rimegepant provides quick and lasting relief from migraine symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhenjiang, China
Conditions
Explore the condition pages connected to this study.